TP53 and Miyoshi myopathy: Finally, we have shown that UNC-0379 treatment leads to a significant lethal synergy with the DNA-damaging agent melphalan and can overcome the resistance associated with this cytotoxic drug in both p53 wild-type and deficient MM cells (Fig. 6).